Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG
Marshall JL. et al, (2025), Nature Communications, 16
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route
Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444
Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.
Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
Satti I. et al, (2022), Nature Communications, 13
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.
Wilkie M. et al, (2022), Scientific reports, 12
Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
Bitencourt J. et al, (2022), Frontiers in Immunology, 12
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination
Bitencourt J. et al, (2021)
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.
Tanner R. et al, (2021), NPJ vaccines, 6
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
Factors affecting the species of Campylobacter colonizing chickens reared for meat.
Babacan O. et al, (2020), Journal of applied microbiology
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M. et al, (2020), Vaccine, 38, 779 - 789
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants.
Müller J. et al, (2019), JCI insight, 4
Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays.
Tanner R. et al, (2019), Scientific reports, 9
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas Z-R. et al, (2019), PLoS medicine, 16